Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 26

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 26
---
 many of which will be beyond its control. In addition to the other information contained in this proxy statement, you should carefully consider the material risks described below before deciding how to vote your shares of MIRA Common Stock. You should also read and consider the other information in this proxy statement. Please see the section titled “Where You Can Find More Information.”

If any of the following risks and uncertainties develop into actual events, these events could have a material adverse effect on the business, financial condition and results of operations of MIRA. In addition, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods.

Risks Related to SKNY

Because SKNY has a limited operating history, you may not be able to accurately evaluate SKNY’s operations.

SKNY has had no operations to date, and therefore, SKNY has a limited operating history upon which to evaluate the merits of investing in SKNY. Potential investors should be aware of the difficulties normally encountered by new companies and the high rate of failure of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and delays encountered in connection with the operations that SKNY plans to undertake. These potential problems include, but are not limited to, unanticipated problems relating to the ability to generate sufficient cash flow to operate SKNY’s business, and additional costs and expenses that may exceed current estimates. SKNY expects to continue to incur significant losses into the foreseeable future. SKNY recognizes that if the effectiveness of its business plan is not forthcoming, it will not be able to continue business operations. There is no history upon which to base any assumption as to the likelihood that SKNY will prove successful, and it is doubtful that SKNY will generate any operating revenues or ever achieve profitable operations. If SKNY is unsuccessful in addressing these risks, SKNY’s business will most likely fail.

SKNY is an early development-stage company with no revenues.

As a very early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, SKNY has generated no revenue to date. There can be no assurance that SKNY will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that SKNY will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about SKNY’s ability to continue as a going concern. The failure to obtain sufficient capital